Published in:
01-03-2008
Inhibition of Airway Allergic Disease by Co-Administration of Flagellin with Allergen
Authors:
Shee Eun Lee, Youngil I. Koh, Mi-Kwang Kim, Young Ran Kim, Soo Young Kim, Jong Hee Nam, Yoo Duk Choi, Soo Jang Bae, Young Jong Ko, Hwa-Ja Ryu, Jeong Tae Koh, Hyon E. Choy, Joon Haeng Rhee
Published in:
Journal of Clinical Immunology
|
Issue 2/2008
Login to get access
Abstract
Bacterial flagellin, which activates Toll-like receptor 5 and cytosolic pattern recognition receptor Ipaf, has a strong immunomodulatory activity. In the present study, we examined whether intranasal co-administration of flagellin with allergen could modulate established airway hyperresponsiveness and Th2 response using an ovalbumin (OVA)-sensitized mouse model. Balb/c mice sensitized with OVA were treated with OVA–flagellin (FlaB) mixture three times at 1-week intervals. Seven days after the final OVA–FlaB administration, the mice were challenged with OVA inhalation, and airway responses and OVA-specific immune responses were evaluated. The OVA–FlaB treatment significantly suppressed OVA-induced airway hyperresponsiveness, airway eosinophilic inflammation, and OVA-specific Th2 cytokine productions in splenocytes. These results indicate that flagellin co-administered with allergen can modulate airway inflammatory response through inhibition of Th2 responses, and flagellin can be considered as a component for allergen-specific immunotherapy.